Business Description
LUMOSA THERAPEUTICS CO LTD
ISIN : TW0006535008
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 66.96 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 72.77 | |||||
Beneish M-Score | -1.67 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 25 | |||||
3-Year EBITDA Growth Rate | 16.2 | |||||
3-Year EPS without NRI Growth Rate | 18.1 | |||||
3-Year FCF Growth Rate | -25.3 | |||||
3-Year Book Growth Rate | -7.4 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 68.57 | |||||
9-Day RSI | 60.16 | |||||
14-Day RSI | 56.53 | |||||
6-1 Month Momentum % | 240.27 | |||||
12-1 Month Momentum % | 349.94 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.75 | |||||
Quick Ratio | 4.28 | |||||
Cash Ratio | 3.85 | |||||
Days Inventory | 2480.92 | |||||
Days Sales Outstanding | 81.99 | |||||
Days Payable | 12.18 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.7 | |||||
Shareholder Yield % | 0.01 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 72.88 | |||||
Operating Margin % | -659.96 | |||||
Net Margin % | -418.23 | |||||
FCF Margin % | -576.66 | |||||
ROE % | -14.99 | |||||
ROA % | -13.02 | |||||
ROIC % | -48.01 | |||||
ROC (Joel Greenblatt) % | -1452.14 | |||||
ROCE % | -15.38 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 541.43 | |||||
PB Ratio | 22.31 | |||||
Price-to-Tangible-Book | 22.32 | |||||
EV-to-EBIT | -121.71 | |||||
EV-to-EBITDA | -134.24 | |||||
EV-to-Revenue | 534.67 | |||||
EV-to-FCF | -82.92 | |||||
Price-to-Net-Current-Asset-Value | 39.64 | |||||
Price-to-Net-Cash | 53.08 | |||||
Earnings Yield (Greenblatt) % | -0.83 | |||||
FCF Yield % | -1.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
LUMOSA THERAPEUTICS CO LTD Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil NT$) | 56.916 | ||
EPS (TTM) (NT$) | -1.47 | ||
Beta | 0.74 | ||
Volatility % | 120.29 | ||
14-Day RSI | 56.53 | ||
14-Day ATR (NT$) | 10.35645 | ||
20-Day SMA (NT$) | 180.325 | ||
12-1 Month Momentum % | 349.94 | ||
52-Week Range (NT$) | 43.4 - 233.5 | ||
Shares Outstanding (Mil) | 164.97 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
LUMOSA THERAPEUTICS CO LTD Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
LUMOSA THERAPEUTICS CO LTD Stock Events
Event | Date | Price(NT$) | ||
---|---|---|---|---|
No Event Data |
LUMOSA THERAPEUTICS CO LTD Frequently Asked Questions
What is LUMOSA THERAPEUTICS CO LTD(ROCO:6535)'s stock price today?
When is next earnings date of LUMOSA THERAPEUTICS CO LTD(ROCO:6535)?
Does LUMOSA THERAPEUTICS CO LTD(ROCO:6535) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |